          |
 |
OMIG Main Page | 2005 Abstracts | < Previous | Next > Linezolid and Daptomycin: Future Ophthalmic Antibiotics? E. G. Romanowski, R. P. Kowalski, F. S. Mah, Y. J. Gordon. The Charles T. Campbell Ophthalmic Microbiology Laboratory, UPMC Eye Center, University of Pittsburgh, Pittsburgh, PA Purpose. We evaluated the in vitro antibacterial activity of the Gram-positive antibiotics linezolid and daptomycin, and compared those with the in vitro antibacterial activity of other commonly used ophthalmic antibiotics used for Gram-positive ocular infections. Methods. The Minimum Inhibitory Concentrations (MICs) of 25 consecutive Staphylococcus aureus endophthalmitis isolates and 25 consecutive Coagulase-Negative Staphylococci (CNS) endophthalmitis isolates were determined for linezolid (LZ), daptomycin (DP), moxifloxacin (MX), gatifloxacin (GA), gentamicin (GM), oxacillin (OX), erythromycin (E), vancomycin (VA), and cephalothm (CP) using E-tests. Susceptibility was interpreted using the CLSI standards. MIC5o and MIC9o determinations are expressed as ug/ml. Results.
Conclusions. Linezolid and daptomycin, along with vancomycin and cephalothin (cefazolin), demonstrated 100% in vitro susceptibility for the Staphylococcus aureus and Coagulase- Negative Staphylococci endophthalmitis isolates tested. Our results suggest that further studies to determine the full potential of these antibiotics in ophthalmology are warranted. Disclosure code:N Support: NIH EY08227, EY08098 OMIG Main Page | 2005 Abstracts | < Previous | Next >
|
|
